SEC
SlamSEC
SearchBrowseEarnings

Moderna, Inc.

Nasdaq:MRNA
Biological Products, (No Diagnostic Substances)·CAMBRIDGE, MA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(1001 total)

TypeDateAccessionPeriodSize
4
Mar 6, 2026
0001682852-26-000051PRIMARY DOCUMENT
Mar 5, 2026
8.4 KB
4
Mar 6, 2026
0001682852-26-000049PRIMARY DOCUMENT
Mar 5, 2026
8.3 KB
8-K
Mar 5, 2026
0001682852-26-0000478-K
Mar 3, 2026
149.1 KB
4
Mar 3, 2026
0001682852-26-000044PRIMARY DOCUMENT
Mar 1, 2026
8.1 KB
4
Mar 3, 2026
0001682852-26-000042PRIMARY DOCUMENT
Feb 27, 2026
30.0 KB
4
Mar 3, 2026
0001682852-26-000040PRIMARY DOCUMENT
Feb 27, 2026
33.4 KB
4
Mar 3, 2026
0001682852-26-000038PRIMARY DOCUMENT
Feb 27, 2026
23.0 KB
144
Mar 2, 2026
0001959173-26-001610
—
4.3 KB
4
Feb 25, 2026
0001682852-26-000036PRIMARY DOCUMENT
Feb 23, 2026
13.4 KB
144
Feb 23, 2026
0001959173-26-001320
—
4.3 KB
S-8
Feb 20, 2026
0001682852-26-000034S-8
—
197.8 KB
10-K
Feb 20, 2026
0001682852-26-00003310-K
Dec 31, 2025
15.0 MB
4
Feb 13, 2026
0001682852-26-000024PRIMARY DOCUMENT
Feb 11, 2026
6.1 KB
4
Feb 13, 2026
0001682852-26-000021PRIMARY DOCUMENT
Feb 11, 2026
6.1 KB
4
Feb 13, 2026
0001682852-26-000019PRIMARY DOCUMENT
Feb 11, 2026
8.0 KB
4
Feb 13, 2026
0001682852-26-000017PRIMARY DOCUMENT
Feb 11, 2026
8.4 KB
8-K
Feb 13, 2026
0001682852-26-0000158-K
Feb 13, 2026
318.3 KB
8-K
Feb 11, 2026
0001682852-26-0000128-K
Feb 3, 2026
170.2 KB
SCHEDULE 13G/A
Feb 9, 2026
0001088875-26-000008
—
7.4 KB
SCHEDULE 13G/A
Feb 6, 2026
0000315066-26-000599
—
11.3 KB
SCHEDULE 13G
Feb 5, 2026
0000315066-26-000495
—
11.1 KB
8-K
Jan 12, 2026
0001682852-26-0000078-K
Jan 12, 2026
175.4 KB
4
Jan 6, 2026
0001682852-26-000005PRIMARY DOCUMENT
Jan 5, 2026
8.3 KB
8-K
Jan 5, 2026
0001682852-26-0000038-K
Jan 5, 2026
233.0 KB
SC TO-I/A
Dec 16, 2025
0001682852-25-000098SC TO-I/A
—
25.0 KB
25 filings shown

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines.

CEO
Bancel Stephane
CFO
Mock James M